前列腺后部剂量降低与PSA进展风险增加相关:三项随机三期试验的体素分析
该研究基于RADAR、RT01和CHHiP三项随机三期试验的683例、388例和253例前列腺癌患者计划剂量分布,将剂量形变配准至同一例模CT后进行体素分析。结果显示,前列腺后部及紧邻后侧周围区域(包括精囊腺)剂量降低与PSA进展风险增加相关,但在CHHiP患者中未观察到该关联。建议在前列腺后部定义边界时注意确保足够剂量覆盖,同时权衡直肠剂量与生活质量。
要点
- 前列腺后部及紧邻后侧周围区域剂量降低与PSA进展风险增加相关。
- 精囊腺区域剂量降低与RADAR中危患者PSA进展风险增加相关。
- CHHiP患者未观察到上述剂量-进展关联,外部验证结果不一致。
核心结论
- 确保前列腺后部及紧邻后侧周围区域(包括精囊腺)的足够剂量覆盖可能改善肿瘤控制。
- 建议在前列腺后部定义边界时特别谨慎,并权衡直肠剂量所致生活质量影响与临床医生及患者偏好。
研究设计与样本
- 研究为基于三项随机三期试验计划剂量分布的体素分析,采用形变配准将剂量分布注册至同一例模CT数据集。
- 分析人群包括RADAR试验683例患者,并分为高危和中危亚组。
- 外部验证纳入RT01试验388例和CHHiP试验253例患者,将剂量分布注册至同一例模后重复统计检验。
- 统计方法包括置换检验、Cox回归建模和最小绝对收缩选择算子特征选择三种独立体素检验。
主要发现
- 体素Cox回归显示,前列腺后部覆盖区域、前列腺后部紧邻周围区域及后斜束或后侧束边界对应区域剂量降低与PSA进展风险增加相关。
- 上述前列腺后部区域剂量降低与PSA进展风险增加的关联在RADAR和RT01患者中观察到,但在CHHiP患者中未观察到。
- 精囊腺区域剂量降低与RADAR中危患者PSA进展风险增加相关。
临床怎么用
- 在前列腺后部及紧邻后侧周围区域(包括精囊腺)制定计划时,应确保足够的剂量覆盖以降低PSA进展风险。
- 在前列腺后部定义边界时需特别谨慎,并权衡直肠剂量所致生活质量影响与临床医生及患者偏好。
局限性
- CHHiP患者中未观察到前列腺后部剂量降低与PSA进展风险增加的关联,外部验证结果不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Reducing margins during treatment planning to decrease dose to healthy organs surrounding the prostate can risk inadequate treatment of subclinical disease. This study aimed to investigate whether lack of dose to subclinical disease is associated with increased disease progression by using high-quality prostate radiation therapy clinical trial data to identify anatomically localized regions where dose variation is associated with prostate-specific antigen progression (PSAP). METHODS AND MATERIALS: Planned dose distributions for 683 patients of the Trans-Tasman Radiation Oncology Group 03.04 Randomized Androgen Deprivation and Radiotherapy (RADAR) trial were deformably registered onto a single exemplar computed tomography data set. These were divided into high-risk and intermediate-risk subgroups for analysis. Three independent voxel-based statistical tests, using permutation testing, Cox regression modeling, and least absolute shrinkage selection operator feature selection, were applied to identify regions where dose variation was associated with PSAP. Results from the intermediate-risk RADAR subgroup were externally validated by registering dose distributions from the RT01 (n = 388) and Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer Trial (CHHiP) (n = 253) trials onto the same exemplar and repeating the tests on each of these data sets. RESULTS: Voxel-based Cox regression revealed regions where reduced dose was correlated with increased prostate-specific androgen progression. Reduced dose in regions associated with coverage at the posterior prostate, in the immediate periphery of the posterior prostate, and in regions corresponding to the posterior oblique beams or posterior lateral beam boundary, was associated with increased PSAP for RADAR and RT01 patients, but not for CHHiP patients. Reduced dose to the seminal vesicle region was also associated with increased PSAP for RADAR intermediate-risk patients. CONCLUSIONS: Ensuring adequate dose coverage at the posterior prostate and immediately surrounding posterior region (including the seminal vesicles), where aggressive cancer spread may be occurring, may improve tumor control. It is recommended that particular care be taken when defining margins at the prostate posterior, acknowledging the trade-off between quality of life due to rectal dose and the preferences of clinicians and patients.
引用
- Marcello M, Denham JW, Kennedy A, et al. Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials. Int J Radiat Oncol Biol Phys. 2020. PMID: 32739320. doi:10.1016/j.ijrobp.2020.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。